DK-TCIP2, linking inhibitor of CDK9 SNS-032 with ligands of BCL6 BI-3812, is a anticancer agent. DK-TCIP2 shows anticancer activity in vivo and in vitro and can be used for study of lymphoma cancer [1].
References:
[1]. Sarott RC, et al. Relocalizing transcriptional kinases to activate apoptosis. Science. 2024 Oct 4;386(6717):eadl5361.
References:
[1]. Sarott RC, et al. Relocalizing transcriptional kinases to activate apoptosis. Science. 2024 Oct 4;386(6717):eadl5361.
















